Beginning with a purpose

I couldn’t be more enthusiastic about our purpose at atHeart Medical: allowing more future options for patients with atrial septal defects (ASDs) by reducing device footprint.

Our first product, the reSept ASD Occluder, is the first occluder with a metal-free, bioresorbable frame.

We are focusing on preparing initial clinical sites for our U.S. IDE pivotal trial, the FDA-approved ASCENT-ASD study.

We want to expand the promising data from initial clinical experience, to establish the new standard of care for the closure of ASDs – a congenital condition affecting six in 10,000 births.

I am excited to lead atHeart Medical’s incredibly experienced team, as we hit the ground running.

Thank you for following us from our very first steps in this exciting new journey.